United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
24/05/2024 22:00:00
|
Chg.
-3.6200
|
Volume |
Bid01:53:57 |
Ask01:53:57 |
Market Capitalization |
Dividend Y. |
P/E Ratio |
272.8800USD
|
-1.31%
|
408,164 Turnover: 57.23 mill. |
267.8300Bid Size: 100 |
277.3100Ask Size: 100 |
12.1 bill.USD |
- |
12.97 |
Business description
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.
Management board & Supervisory board
CEO |
Dr. Martine A. Rothblatt |
Management board |
James C. Edgemond, Michael Benkowitz, Paul A. Mahon |
Supervisory board |
Dr. Martine A. Rothblatt, Christopher Causey, Christopher Patusky, Dr. Judy D. Olian, Dr. Katherine J. Klein, Linda Maxwell, M.D., Louis Sullivan, Nilda Mesa, Prof. Raymond Dwek, Ray Kurzweil, Richard Giltner, Tommy G. Thompson |
Company data
Name: |
United Therapeutics Corporation |
Address: |
1040 Spring Street,Silver Spring, Maryland 20910, USA |
Phone: |
+1-301-608-9292 |
Fax: |
+1-301-608-9291 |
E-mail: |
-
|
Internet: |
is.gd/1hUSaA |
Industry: |
Biotechnology |
Sector: |
Biotechnology |
Sub sector: |
Biotechnology |
End of financial year: |
31/12 |
Free Float: |
61.80% |
IPO date: |
- |
Investor relations
Name: |
- |
IR phone: |
- |
IR Fax: |
- |
IR e-mail: |
ir@unither.com
|
Main Shareholders
Freefloat |
|
61.80% |
BlackRock, Inc |
|
9.60% |
The Vanguard Group |
|
8.90% |
Renaissance Technologies LLC |
|
8.10% |
Avoro Capital Advisors LLC |
|
6.40% |
FMR, LLC |
|
5.20% |